Baricitinib versus Hydroxychloroquine for Cutaneous Lichen Planus: An Assessor-Blind Randomized Clinical Trial

Clicks: 4
ID: 314187
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #116 of 176 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 176 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Lichen planus (LP) is a chronic autoimmune inflammatory disorder with limited effective long-term treatment options. Hydroxychloroquine has been widely used as systemic therapy, while baricitinib, a Janus kinase 1/2 inhibitor, has shown promise in refractory cases, but comparative evidence is lacking. Objective This study aimed to compare the efficacy and safety of baricitinib versus hydroxychloroquine in patients with cutaneous lichen planus. Methods In this randomized controlled trial, 32 patients with cutaneous LP were randomized to baricitinib 4 mg once daily or hydroxychloroquine 200 mg twice daily for 12 weeks. The primary outcome was the change in Lichen Planus Activity and Damage Index (LiPADI). Secondary outcomes included pruritus severity, patient satisfaction, and Physician Global Assessment (PGA). Results Both groups showed significant improvement in pruritus severity and LiPADI scores (P<0.001). Mean LiPADI scores decreased from 14.2 to 1.1 with baricitinib and from 12.2 to 5.3 with hydroxychloroquine (P=0.029), indicating a greater reduction in disease activity for baricitinib. Pruritus VAS improved from 8.3 to 0.2 in the baricitinib group and from 8.8 to 3.3 with hydroxychloroquine (P<0.001). Patient satisfaction increased from 4.5 to 8.8 and from 4.6 to 6.9, respectively (P = 0.001). Global Physician Assessment improved in both groups, but the between-group difference was not statistically significant (P=0.376). No major or life-threatening adverse events were observed in both groups. Conclusion In this assessor-blinded randomized trial, both baricitinib and hydroxychloroquine improved cutaneous lichen planus over 12 weeks. Baricitinib was associated with greater short-term improvementin disease activity and pruritus, along with higher patient satisfaction, without evidence of additional short-term safety concerns. The small sample size, short follow-up, and non-double-blind design warrant cautious interpretation. Larger double-blind studies with longer follow-up are needed.
Reference Key
openalex_W7161886870 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Hossein Kargar, Mohammad Ali Esfandiari, Mehdi Ghahartars, Mohammad Mahdi Parvizi
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag210
URL
https://doi.org/10.1093/ced/llag210
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.